Astellas seeks FDA approval for tacrolimus tablets
Tacrolimus, developed by Astellas, is a once daily formulation of calcineurin-inhibitor immunosuppressant tacrolimus. Astellas global transplantation therapeutic area head Roy First said there remains a large unmet treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.